Travere Therapeutics, Inc. (TVTX) is listed on NASDAQ in Pharmaceutical Stocks. It is $65.68, -2.73%, with a $6.2B market cap. RSI is 62.9, near overbought. The latest reported quarter missed estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 62.9 Near Overbought
Market Cap $6.2B
Volume 676.1K
Fundamentals — 10-Q Q2 2026
Revenue $296.8M
Net Income $-71.9M
EPS $-0.78
Gross Margin 98.6%
Operating Margin -11.1%
Net Margin -24.2%
P/E Ratio -84.2x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Lyons Gary A | Insider | Sell | 10,000 | $63.28 | $632,846 | 2026 Aug 18 |
| Coughlin Timothy | Insider | Sell | 10,000 | $50.07 | $500,747 | 2026 Jun 12 |
| Baynes Roy D. | Insider | Sell | 4,500 | $50.00 | $225,000 | 2026 Jun 12 |
| Rote William E. | Chief Research Officer | Sell | 2,763 | $43.95 | $121,434 | 2026 May 6 |
| Reed Elizabeth E | Chief Legal Officer and GC | Sell | 24,250 | $45.06 | $1.1M | 2026 May 6 |
| Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 22,485 | $45.15 | $1.0M | 2026 May 6 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 22,500 | $43.95 | $988,875 | 2026 May 6 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 2,491 | $46.31 | $115,368 | 2026 May 6 |
| Baynes Roy D. | Insider | Sell | 4,500 | $46.65 | $209,925 | 2026 May 5 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 2,174 | $46.65 | $101,417 | 2026 May 5 |
| Meckler Jeffrey A | Insider | Sell | 8,000 | $45.00 | $360,000 | 2026 May 4 |
| Baynes Roy D. | Insider | Sell | 9,750 | $44.22 | $431,145 | 2026 May 1 |
| Rote William E. | Chief Research Officer | Sell | 9,100 | $39.09 | $355,719 | 2026 Apr 22 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 64,000 | $41.09 | $2.6M | 2026 Apr 15 |
| Reed Elizabeth E | Chief Legal Officer and GC | Sell | 51,500 | $41.29 | $2.1M | 2026 Apr 15 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 8,327 | $41.91 | $348,974 | 2026 Apr 15 |
| Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 8,233 | $42.01 | $345,893 | 2026 Apr 15 |
| Lyons Gary A | Insider | Sell | 8,000 | $41.07 | $328,560 | 2026 Apr 14 |
| Baynes Roy D. | Insider | Sell | 32,750 | $41.29 | $1.4M | 2026 Apr 14 |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 21,977 | $41.07 | $902,595 | 2026 Apr 14 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $40.94 | 41.9 | $5.5B |
| | $33.21 | 63.0 | -- |
| | $280.77 | 42.4 | $5.6B |
| | $105.79 | 46.8 | $5.9B |
| | $34.67 | 38.7 | $6.0B |
Take TVTX further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put TVTX in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Travere Therapeutics, Inc. next reports.
Set alerts on TVTX
Get notified when Travere Therapeutics, Inc. hits your price targets or technical conditions are met.
Get Started Free